Rheumatology: Current Research
Open Access

Abstract

Semaphorin 3A in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients

Nancy A Mohamed, Radwa M Elkhouly, Mohamed E Mowafy and Wessam S Ibrahim

The aim of this study is to evaluate Semaphorin 3A level in rheumatoid arthritis and systemic lupus and its correlation with clinical, laboratory markers of disease activity and extra articular manifestations. Fifteen (RA) patients GROUP I and fifteen (SLE) patients GROUP II with age and sex matched fifteen healthy volunteers who served as controls GROUP III were studied. Disease activity score was used to assess disease activity in RA and SLE patients, MHAQ, RF and ANTICCP were measured for RA patients. Also ANA, Anti-dsDNA was measured for SLE patients. The serum level of semaphoring 3A was assessed by (ELISA) technique for the RA, SLE patients and control group. Group II SLE patients had significant decrease in serum level of semaphoring 3A versus group I RA patients and control group also there was significant decrease in semaphorine 3 A level in group I in RA in comparison with control group. There were significant negative correlation between Semaphorin 3A and disease duration, laboratory markers of disease activity (ESR1st h,CRP) and grades of disease activity (DAS28). There were significant negative correlation between Semaphorin 3A and SLEDAI score, ANA, anti-dsDNA and renal affection (proteinuria) in SLE patients.